「177Lu」Lu-HA-DOTATATE 治疗后的外渗
本文报告一例74岁神经内分泌肿瘤女性患者,经右上臂静脉输注7.4 GBq「177Lu」Lu-HA-DOTATATE期间因导管移位发生放射性药物外渗。平面显像显示右上臂放射性积聚,24小时后肿胀减轻但红斑加重,1周后症状消失,11个月随访期内未出现任何并发症。
要点
- 肽受体放射性核素治疗输注中放射性药物外渗是罕见不良事件。
- 7.4 GBq「177Lu」Lu-HA-DOTATATE经右上臂输注时导管移位致外渗,平面显像示右上臂放射性积聚。
- 外渗后24小时肿胀减轻但红斑加重,1周后症状消失,11个月随访无并发症。
核心结论
- 本文报告一例「177Lu」Lu-HA-DOTATATE输注中外渗的病例,患者11个月随访期内未出现任何并发症。
研究设计与样本
- 病例报告:一例74岁神经内分泌肿瘤女性患者接受肽受体放射性核素治疗。
主要发现
- 经右上臂静脉输注7.4 GBq「177Lu」Lu-HA-DOTATATE期间,因静脉导管移位发生放射性药物外渗。
- 平面显像显示右上臂放射性积聚。
- 外渗后24小时右上臂肿胀减轻,但红斑加重。
- 1周后症状消失,11个月随访期内患者未出现任何并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.
引用
- de Vries-Huizing DMV, Cheung ZJ, Hendrikx JJMA, et al. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy. Clin Nucl Med. 2024. PMID: 38465961. doi:10.1097/RLU.0000000000005137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。